Interested in discontinuing your injectable GLP-1?
Learn about a clinical trial for an oral investigational medicine for weight maintenance that may allow you to stop taking an injectable GLP-1 treatment. Study-related care may be provided at no cost, and compensation may be available for time, travel, and other expenses.
Space is limited—apply today to see if you qualify.
You may be eligible if you:
- Are between 18 and 80 years of age
- Have been taking a brand name, injectable GLP-1 (semaglutide or tirzepatide) continuously for more than 6 months
- Had a documented BMI of 30 kg/m² or higher before starting your GLP-1, or BMI of 27 kg/m² with one weight-related comorbidity like hypertension, high cholesterol, cardiovascular disease or obstructive sleep apnea
- Have reduced at least 10% of your body weight since you’ve started taking a GLP-1
- Are willing to discontinue use of your current injectable GLP-1 during the study
Additional criteria may apply. A full list of study criteria will be reviewed with you by our team.
Qualified Participants May Receive:
- Access to oral investigational medicine
- Compensation for time, travel and other expenses
- Study-related care at no cost
- The opportunity to help advance potential new options for reducing body weight
Participation is voluntary.
Study Location:
These studies are taking place in Stamford, CT.
How to Apply:
Submit your information using our form on the right side of this page. A member of our friendly team will reach out to discuss next steps and answer your questions.
Research Study:
Maintaining Weight Loss After Discontinuing a GLP-1
Compensation
May be available for time, travel and other expenses for those who qualify. No cost to participate.
Eligible Ages
Open to adults aged 18 – 80.